Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →SEED Therapeutics scored a $1.5 billion biobucks collaboration with Eisai, marking the biotech's second major pharma partnership following a 2022 deal with Eli…
Japan's Eisai said on Tuesday it has entered a strategic research collaboration with U.S. biotech SEED Therapeutics to discover novel molecular glue degraders…
Eisai is reaching beyond its Leqembi Alzheimer's franchise with a $1.5 billion molecular glue collaboration with SEED Therapeutics, including a Series…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
SEED Therapeutics entered strategic research collaboration with Eisai to discover molecular glue degraders for undisclosed neurodegeneration and oncology targets. SEED eligible for upfront plus preclinical, clinical, regulatory and sales milestones up to $1.5B plus tiered royalties. Also launched Series A-3 financing led by Eisai with $24M first close. Post-announcement, SEED completed the financing as a $30M Series A-3 ($24M first close Aug 2024 + $6M second close Aug 2025) and advanced its broader RITE3 molecular-glue platform: FDA cleared the IND for internal lead ST-01156 (RBM39 degrader) in Aug 2025 and the first Phase 1 patient (NCT07197554) was dosed Jan 2026. The Eisai collaboration remains a pending option-bearing research alliance — Eisai stays a cornerstone investor/collaborator and the $1.5B in biobucks is contingent on Eisai exercising exclusive rights on the undisclosed targets, which remain preclinical.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eisai Co., Ltd. / SEED Therapeutics Inc. (this deal) | 2024 | $1.5B | — |
| Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) | 2006 | $205M | 41 |
| Eisai Co., Ltd. / MGI Pharma Inc. | 2007 | $3.9B | 36 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2024 deals · Eisai Co., Ltd. deals · Neurology deals